Co-Diagnostics reports cash, equivalents of $58.5M as of December 31, 2023

“We are pleased to have made great progress towards our strategic goals in the fourth quarter, highlighted by an Emergency Use Authorization submission to the FDA for our Co-Dx PCR Pro instrument, mobile app, and COVID-19 test,” said Dwight Egan, Co-Diagnostics’ CEO. “We believe that our EUA submission will serve as a steppingstone in our effort to decentralize PCR diagnostics and to expand to the point-of-care and at-home settings. Co-Diagnostics’ investment in additional production capacity in Salt Lake City also includes the manufacturing of our Co-Primers in-house, to lower costs. We are currently building expanded capacity for test cup and instrument manufacturing lines in India as well, in addition to capability to support Co-Primers manufacturing in the near future.” “We remain excited for 2024 and look forward to providing updates on our test development and platform. Co-Diagnostics plans to continue the development of our TB, multiplex respiratory, and HPV tests throughout the year,” said Brian Brown, Co-Diagnostics’ CFO.